comparemela.com

Latest Breaking News On - ஜெசிகா ஹோட்சன் - Page 4 : comparemela.com

Investegate |Synairgen plc Announcements | Synairgen plc: Result of AGM

Investegate |Synairgen plc Announcements | Synairgen plc: Result of AGM
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United-kingdom
Carina-jurs
Geoff-nash
Mary-conway
John-ward
Richard-marsden
Donna-davies
Duncan-monteith
Jessica-hodgson
James-black
Mary-jane-elliott
Kate-bannatyne

Creo Appoints Industry Leader Joel Cherry as Chief Technology Officer

Creo Appoints Industry Leader Joel Cherry as Chief Technology Officer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

California
United-states
Kostenloser-wertpapierhandel
Jessica-hodgson
Mary-jane-elliott
Lindsey-neville
Roy-lipski
Matthew-cole
Technology-officer
Novo-nordisk
Consilium-strategic-communications
Chief-technology

Investegate |Creo Announcements | Creo: Creo Appoints Industry Leader Joel Cherry as Chief Technology Officer

Investegate |Creo Announcements | Creo: Creo Appoints Industry Leader Joel Cherry as Chief Technology Officer
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

California
United-states
Jessica-hodgson
Mary-jane-elliott
Lindsey-neville
Roy-lipski
Matthew-cole
Technology-officer
Novo-nordisk
Consilium-strategic-communications
Creo-appoints-industry-leader-joel-cherry
Chief-technology

Investegate |Sensyne Health PLC Announcements | Sensyne Health PLC: Trading Update

Real world patient database and revenues rapidly growing Sensyne poised for accelerated international growth   Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company ), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ( FY 2021 ), and an outlook statement.   UPDATE ON TRADING · Robust financial performance: FY 2021 unaudited revenues of at least £9.0 million (FY 2020: £2.1 million audited). · Strong revenue growth driven by contracts with life sciences companies, with recognition of the majority of the £4.8 million minimum revenues from MagnifEye AI technology contract with Excalibur Health Services ( Excalibur ). · Cash and cash equivalents were £23.6 million (unaudited) and excludes receipt of majority of minimum revenue payments from the Excalibur contract (FY 2020: £31.7 million au

Colorado
United-states
Pennsylvania
New-jersey
United-kingdom
Bidhi-bhoma
Euan-brown
Jessica-hodgson
Richard-pye
Mary-jane-elliott
Oliver-jackson
Asia-pacific

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.